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Background: Repetitive hypoxic preconditioning (RHP) creates an anti-inflammatory phenotype that protects from
stroke-induced injury for months after a 2-week treatment. The mechanisms underlying long-term tolerance are
unknown, though one exposure to hypoxia significantly increased peripheral B cell representation. For this study,
we sought to determine if RHP specifically recruited B cells into the protected ischemic hemisphere, and whether
RHP could phenotypically alter B cells prior to stroke onset.
Methods: Adult, male SW/ND4 mice received RHP (nine exposures over 2 weeks; 8 to 11 % O2; 2 to 4 hours) or
identical exposures to 21 % O2 as control. Two weeks following RHP, a 60-minute transient middle cerebral artery
occlusion was induced. Standard techniques quantified CXCL13 mRNA and protein expression. Two days after
stroke, leukocytes were isolated from brain tissue (70:30 discontinuous Percoll gradient) and profiled on a BD-FACS
Aria flow cytometer. In a separate cohort without stroke, sorted splenic CD19+ B cells were isolated 2 weeks after
RHP and analyzed on an Illumina MouseWG-6 V2 Bead Chip. Final gene pathways were determined using Ingenuity
Pathway Analysis. Student’s t-test or one-way analysis of variance determined significance (P < 0.05).
Results: CXCL13, a B cell-specific chemokine, was upregulated in post-stroke cortical vessels of both groups. In the
ischemic hemisphere, RHP increased B cell representation by attenuating the diapedesis of monocyte, macrophage,
neutrophil and T cells, to quantities indistinguishable from the uninjured, contralateral hemisphere. Pre-stroke
splenic B cells isolated from RHP-treated mice had >1,900 genes differentially expressed by microarray analysis.
Genes related to B-T cell interactions, including antigen presentation, B cell differentiation and antibody production,
were profoundly downregulated. Maturation and activation were arrested in a cohort of B cells from pre-stroke
RHP-treated mice while regulatory B cells, a subset implicated in neurovascular protection from stroke, were
upregulated.
Conclusions: Collectively, our data characterize an endogenous neuroprotective phenotype that utilizes adaptive
immune mechanisms pre-stroke to protect the brain from injury post-stroke. Future studies to validate the role of B
cells in minimizing injury and promoting central nervous system recovery, and to determine whether B cells mediate
an adaptive immunity to systemic hypoxia that protects from subsequent stroke, are needed.
Keywords: Hypoxic preconditioning, B cells, CXCL13, Stroke, Neuroprotection, B10* Correspondence: Ann.Stowe@utsouthwestern.edu
Department of Neurology and Neurotherapeutics, University of Texas
Southwestern Medical Center at Dallas, 6000 Harry Hines Blvd, Dallas, TX
75390-8813, USA
© 2014 Monson et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
Monson et al. Journal of Neuroinflammation 2014, 11:22 Page 2 of 18
http://www.jneuroinflammation.com/content/11/1/22Background
Repetitive hypoxic preconditioning (RHP) is a protocol that
induces a naturally-protective phenotype in mice – prior to
stroke onset – that defends the central nervous system
(CNS) from ischemic damage months beyond the end of
treatment [1]. The benefits of RHP include the attenuation
of blood–brain barrier (BBB) disruption and the reduction
of inflammation in the injured, ischemic hemisphere, both
of which contribute to the ultimate extent of stroke
damage and infarct volume [2-4]. Given that RHP is a
systemic stimulus, it stands to reason that peripheral
leukocyte subsets may also be altered in RHP-treated
mice to minimize post-stroke inflammatory responses.
In fact, we recently reported that exposing mice to a single
bout of hypoxia, which induces a short-lasting period of
tolerance to stroke, significantly increased peripheral B
cell representations within hours in either wild-type or
transgenic mouse strains [5].
The role of B cells in stroke is largely overlooked in
preclinical studies, despite the fact that B cell transfer
inhibits the diapedesis of T cells, neutrophils, monocytes,
and macrophages into the ischemic hemisphere, concomi-
tant with reduced infarct volumes and functional deficits,
in B cell-deficient mice [6-9]. Instead, the common view
remains that B cells do not contribute to the progression
of stroke pathology [10-12], and therefore potential
therapeutics should focus on the role of T cells in acute
neurovascular injury [10,13,14]. As a result, there are
also no studies investigating the post-stroke role of
CXCL13, a chemokine that specifically recruits B cells
during inflammation. CXCL13 is upregulated in the CNS
by infiltrating immune cells at sites of multiple sclerosis
lesions [15] and in preclinical studies during CNS infec-
tion [16,17]. These data, taken together with the robust B
cell proliferation after one hypoxic exposure, suggest the
undiscovered potential for a B cell-mediated protective
immunosuppression following RHP treatment in pre-
conditioned mice [18].
In this study, we tested the hypothesis that RHP creates
a sustained, anti-inflammatory immunophenotype in
protected mice. We investigated the spatial and temporal
expression of CXCL13 message and protein in the
post-stroke brain. We also determined the dynamics of
leukocyte diapedesis into the injured CNS during ischemic
tolerance to stroke using flow cytometry techniques. To
establish whether RHP altered adaptive immune mecha-
nisms in the healthy animal, we isolated splenic B cells
from preconditioned and untreated mice for microarray
analysis. We found an enhanced representation of B cells
in the post-stroke CNS of RHP-treated mice. We also
identified a novel, anti-inflammatory B cell phenotype
residing for weeks after the last hypoxic exposure − an
immunophenotype that may induce protection from
ischemic injury in other organ systems, or suppressinflammation during other CNS pathologies. Collectively,
these data reveal long-term mechanisms of endogenous
CNS protection that include an immunosuppression and
reprogramming of B cells occurring prior to stroke onset,
with the potential for a novel, B cell-mediated protection
within the ischemic cortex of RHP-treated mice.
Methods
Repetitive hypoxic preconditioning
The Institutional Animal Care and Use Committee at UT
Southwestern Medical Center approved all procedures
according to the Animal Welfare Act and PHS Animal
Welfare Assurance requirements. Adult, male Swiss Webster
mice (Harlan) were randomly assigned to either RHP or
control groups at 6 to 7 weeks of age. During RHP, home
cages were placed in hypoxic chambers and mice were
exposed to stochastic hypoxic stimuli as previously de-
scribed (8% or 11% O2; 2 or 4 hours; nine times over 2
weeks) [1], with control animals placed in identical
chambers with 21% O2 (that is, room air) delivered for
the same durations as the RHP group.
Transient middle cerebral artery occlusion
An intraluminal suture was inserted in the common carotid
artery to block blood flow to the middle cerebral artery
(MCA) in anesthetized animals (2% isoflurane/70% NO2/
30% O2) while body temperature was maintained at 37°C.
Occlusion duration was 60 minutes. Animals were placed
into an incubator (34°C) for anesthetic recovery during the
occlusion period, then re-anesthetized to withdraw the
occluding suture. Transcranial Laser Doppler flowmetry
(Moor Instruments,Wilmington, DE, USA) was used to
assess MCA occlusion at the start and end of the occlusion
period, with occlusion defined as >80% reduction in MCA
blood flow relative to baseline for each animal. MCA reper-
fusion following suture removal was defined as a return of
blood flow to >50% of baseline. Mice not meeting the blood
flow criteria were removed from the study at the time of
surgery (17 out of 57 mice, 30%). Sham animals had com-
mon carotid artery ligation in the absence of transient mid-
dle cerebral artery occlusion (tMCAo). Mice were
monitored for recovery from anesthesia, then returned
to their home cages.
Histology and confocal CXCL13 localization and
quantification
Animals were sacrificed with isoflurane overdose, trans-
cardially perfused (20 ml 0.01 M PBS, 40 ml 4% para-
formaldehyde), and brains removed for cryoprotection
(15% and 30% sucrose). Frozen coronal sections were
prepared, blocked, and stained using standard procedures
[1,5]. Primary antibodies and dilutions were: CXCL13
(initial concentration 1:20; final concentration 1:10; R&D
Systems, Minneapolis, MN, USA), astrocytes (GFAP 1:200;
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Millipore, Billerica, MA, USA) and endothelial cells (CD31
1:50; BD Pharmingen, San Jose, CA, USA) [5]. Primary
antibodies were detected using Alexa Fluor 488 or 594
(1:300; Invitrogen, Grand Island, NY, USA) and nuclei
were counterstained with DAPI. All images were obtained
using a Leica TCS SP5 confocal laser-scanning microscope
(Leica, Buffalo Grove, IL, USA).
Flow cytometry
Submandibular peripheral blood collections were pooled
into heparinized blood collection tubes (3 mice/sample),
resuspended in 50 μl PBS, and centrifuged at room
temperature to separate serum from cells. Blood was
transferred to FACS tubes, non-specific binding blocked
with FcRγII/III antibody (BD Biosciences, San Jose, CA,
USA) and subsequently incubated with the general
leukocyte panel listed below [19] diluted in FACS buffer.
Blood was then incubated in FACS Lysing Solution (1:10
in dH2O; BD Biosciences) at room temperature for 5
minutes, centrifuged (1,500 rpm), and washed again in
FACS before analysis on the flow cytometer.
Animals were sacrificed with isoflurane overdose and
transcardially perfused with 30 ml 0.01 M PBS as previ-
ously described [5] prior to brain dissection. At the time of
perfusion, animals that did not clear all visible blood from
the contralateral, healthy hemisphere and the sinuses were
excluded from further flow cytometry analyses (4 out of 31
mice, 13 %). Tissue was processed through a 70-μm mesh
screen, washed in RPMI, and lymphocytes were isolated
with a 70:30 discontinuous Percoll gradient by centrifuga-
tion (2,120 g, 15 minutes, brake off). Lymphocytes were
isolated from brain tissue of either the ischemic or
contralateral cortex, with a pooling of three ischemic
or contralateral hemispheres in each sample to ensure
adequate leukocyte populations for flow analysis. The
Percoll gradient does not distinguish between resident and
infiltrating immune cells for either condition. After final
RPMI washes, cells were resuspended in 1 ml RPMI on
ice and cellularity determined by hemocytometer count
for each sample. Nonspecific binding was blocked with an
FcRγII/III antibody (0.5 μl/sample; BD Biosciences). The
general leukocyte panel (BD Biosciences), which does not
distinguish between resident activated microglia and mac-
rophages, included CD19 (B cells; 4.0 μl/sample), CD11b
(monocytes/macrophages; 0.5 μl/sample), GR1 (neutro-
phils; 0.5 μl/sample), CD4 and TCRβ (T cells; 0.5 μl/
sample) [19]. For B cell panels, lymphocytes were iso-
lated using Lympholyte-M (Cedarlane labs, Burlington,
NC, USA), washed with FACS staining buffer, and blocked
with FcRγII/III antibody. For the B-cell activation and
maturation panel, cells were labeled with CD19, IgD
(5.0 μl/sample), CD93 (2.5 μl/sample), CD23 (0.5 μl/
sample; all eBioscience, San Diego, CA, USA) and CD45R(1.0 μl/sample), IgM (2.0 μl/sample), and CD138 (10 μl/
sample; all BD Bioscience) antibodies [20-22]. For the
B-regulatory panel, cells were labeled with CD5 (2.0 μl/
sample; eBioscience), CD45R, CD19, CD1d (0.5 μl/sample)
antibodies [9,23,24]. After a 45-minute incubation at 4°C,
cells were washed with FACS wash buffer (PBS with 1%
BSA, 0.22 μm filtered) and fixed in 1% paraformaldehyde
(Electron Microscopy Sciences, Hatfield, PA, USA). All
samples were run on a BD-FACS Aria flow cytometer using
FACS Diva 6.0 software and data analyzed using FlowJo
(Tree Star Inc., Ashland, OR, USA). Hemocytometer
counts were used to quantify absolute number.
Quantification of message RNA and protein expression
and microarray analysis
Brain lysates were collected at time of flow cytometry
analysis of cortical tissues for quantification of cortical
protein expression. Quantitative immunoassays of these
proteins were performed with standard ELISA kits (R&D
Systems) according to the manufacturer’s instructions. Sep-
arate cohorts were transcardially perfused (20 ml RNAse-
free PBS), brains removed and flash-frozen for quantitative
PCR. CXCL13 mRNA expression was normalized against
β-actin [1]. In a separate cohort, animals were exposed to
RHP or room air and CD19+ B cells were sorted from
spleen at 2 weeks following the last hypoxic exposure. RNA
was isolated and underwent two-rounds of amplification
prior to quantification on an Illumina MouseWG-6 V2
array (San Diego, CA, USA) at the UT Southwestern
Microarray Core. Detectable genes were normalized
(Partek Genomics Suite, St. Louis, MO, USA), with final
between-group significance of the 18,099 genes detected
determined via a restricted maximum likelihood analysis
of variance. Gene ontology pathways were analyzed using
Ingenuity Pathway Analysis.
Carboxyfluorescein succinimidyl ester-based proliferation
As previously described, but adapted for B-cells, polyclonal
responses were evaluated using the carboxyfluorescein
succinimidyl ester (CFSE)-based dilution assay using bulk
splenocytes from RHP or control mice [25]. Bulk cells
were suspended at a 1 × 106/ml concentration in PBS
and incubated for 7 minutes with 0.12 μM CFSE. Cells
were washed twice with serum-containing media and re-
suspended at 1 × 106/ml concentration in culture media.
Cells were activated with lipopolysaccharide (LPS) at 4 μg/
ml or phorbol myristate acetate at 2 μg/ml at 37°C in 5%
CO2 for 6 days. Subsequently, cells were washed with
FACS wash buffer (PBS with 1% BSA, 0.22 μm filtered),
incubated for 5 minutes at 4°C with FcRγII/III antibody
(BD Bioscience) and labeled with CD19, CD45R, TCRβ
and CD4 fluorescent antibodies. After 45 minutes incuba-
tion at 4°C, cells were washed with wash buffer and fixed
in 1% paraformaldehyde (Electron Microscopy Sciences).
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Aria flow cytometer using FACS Diva 6.0 software.
FlowJo 9.0 software was used to gate on Lymphocyte
Gate+ CD19+CD45+TCRβ- and polyclonal-specific re-
sponses analyzed within the CFSE-low population.
Statistics
All studies were performed by technicians blinded to ex-
perimental condition. All between-group differences were
analyzed using student t-test or one-way analysis of
variance with Bonferroni post-hoc analysis (Prism). Signifi-
cance was defined as P < 0.05.
Results
Repetitive hypoxic preconditioning enhances stroke-induced
vascular upregulation of CXCL13 in the ischemic hemisphere
The chemokine CXCL13 specifically recruits B cells for
diapedesis into brain parenchyma, and is upregulated by
inflammatory mechanisms in multiple sclerosis [10,15].
However, the expression of CXCL13 during CNS inflam-
mation within the post-stroke ischemic cortex is unknown.
We first sought to determine the baseline mRNA expres-
sion of CXCL13, by quantitative real-time PCR, in cortical
homogenates (that is, neocortex and underlying white mat-
ter) and subcortical homogenates (for example, striatum,
hippocampus, thalamus, and cerebral ventricles). In general,
subcortical CXCL13 expression was higher than cortical
CXCL13 expression in both untreated (that is, exposed to
room air, or 21% O2 as designated in the Figures) and
RHP-treated cohorts (both P < 0.0001; Figure 1A). In the
absence of stroke, RHP completed 2 weeks prior did not
significantly affect baseline CXCL13 expression in either
cortex or subcortex compared to untreated controls. One
day after stroke induction, there was a 4-fold upregulation
of CXCL13 mRNA in the cortex of RHP-treated miceFigure 1 CXCL13 is upregulated after stroke. (A) Baseline levels of CXCL13
hypoxic preconditioning (RHP; n = 12) completed 2 weeks prior in either cortica
homogenates of the same animals. RHP upregulated cortical CXCL13 message
values were elevated in both groups by 2 days (2D; n = 8, 21 % O2; n = 9, RHP).
cytometry, shows an upregulation at 1 day following stroke (n = 3/group) that r
to sham values (n = 5/group). P values and fold change (#X) shown for significompared to no-stroke values (P < 0.05). Upregulation
of CXCL13 mRNA was not significant in the cortex of
untreated mice and not observed in the subcortex of either
group (Figure 1A). By 2 days following stroke onset, cortical
CXCL13 message was elevated in both untreated and
RHP-treated groups (both P < 0.01).
To determine if RHP affected post-stroke CXCL13
protein expression, we also analyzed cortical lysates col-
lected from the ischemic hemispheres to measure
CXCL13 protein following stroke induction. One day
after stroke induction, a >1.5-fold increase in CXCL13
protein was found in the ischemic cortex, with the mag-
nitude of expression unaffected by prior RHP (both
groups P < 0.0001 vs sham stroke; Figure 1B). RHP-
treated mice maintained a 56 % increase in cortical
CXCL13 protein at 2 days following stroke (P < 0.05).
Immunohistochemistry revealed a predominantly vascu-
lar pattern of CXCL13 protein expression throughout
the ischemic brain following stroke (Figure 2). Specific-
ally, the protein was colocalized largely to CD31+ endo-
thelial cells (Figure 2A) within GFAP+ astrocytic endfeet
at the BBB (Figure 2B,D), with minimal colocalization to
astrocyte cell bodies and non-glial cells, including neu-
rons (Figure 2C,E). Together, these data suggest an ac-
tive role for the cerebral endothelium in the expression
of the CXCL13 within the ischemic cortex.Repetitive hypoxic preconditioning maintains B cells in
the ischemic hemisphere with concomitant reductions in
other leukocyte subsets
To determine the impact of RHP on lymphocyte dynamics,
we harvested leukocytes to investigate the post-stroke accu-
mulation of immune cells in the injured ischemic (that is,
site of tMCAo infarction) and uninjured (that is, contra-
lateral, contralesional) hemispheres 2 days post-strokemRNA (n = 11), prior to transient focal stroke, were unaffected by repetitive
l (left of dashed line) or subcortical (right of dashed line) whole brain
at 1 day (1D) after stroke onset (n = 6, 21 % O2; n = 7, RHP), though cortical
(B) CXCL13 protein, quantified in whole brain lysates collected during flow
emains elevated at 2 days only in RHP-treated mice (n = 5/group) compared
cant values. All mRNA and ELISA experiments were run in triplicate.
Figure 2 CXCL13 is predominantly expressed in the cortical endothelium after stroke. Representative confocal images of cortical CXCL13
protein (red; 594 nm) colocalized with (A) endothelial cells (CD31; green; 488 nm), (B) astrocytes (GFAP; green) and (C) neurons (NeuN; green) 24
hours following stroke at time of peak protein expression. DAPI (blue; 405 nm) was used as a nuclear counterstain and shown in the merge panel.
Note the predominately vascular expression of CXCL13 at the blood–brain barrier in both control mice (top row of each pair) and repetitive hypoxic
preconditioning (RHP)-treated mice (bottom row of each pair). Scale bar = 20 μm; n = 3/group; duplicate staining. Zoomed images from adjacent
sections show distinct colocalization with (D) CD31 and (E) CXCL13 expression within GFAP + astrocyte endfeet. (F) Zoomed image of the corpus
callosum (pale band within NeuN + staining) shows neurons with punctuate CXCL13 staining denoted by white asterisks. Scale bar for zoomed
images = 30 μm. Images were captured using a Leica TCS SP5 confocal microscope with automated DIC optics, a 63× oil objective and LAS AF
software, at 21 °C. Final figures were created using Adobe Photoshop without gamma adjustments. tMCAo, transient middle cerebral artery occlusion.
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had an average of 115,925 leukocytes in the ischemic
brain (Figure 3A), more than double the leukocytes
present in the uninjured hemisphere (50,350 leukocytes;
P < 0.05; contralateral scatter plots and all percent distri-
bution profiles are shown in Additional file 2: Figure S2).
Of the leukocytes that diapedesed into the ischemic cortex,
92,399, or 83%, were identified by flow cytometry using our
leukocyte panel, which distinguishes innate (monocytes,
macrophages, neutrophils) and adaptive (T helper (CD4+),
T cytotoxic (CD8), B cells) immune cells (Figure 3B-G).
Leukocyte subsets in the untreated brain following stroke
were predominantly monocytes (~48%), B cells (~31%),
activated macrophages (~17%), and smaller populations of
neutrophils, CD4+ and CD8 T cells (Figure 3H). In un-
treated mice, the contralateral hemisphere leukocyte sub-
sets (Figure 3J) consisted predominantly of B cells (~47%),
monocytes (~37%), and activated macrophages (~14%).
RHP treatment reduced general diapedesis into the
ischemic hemisphere by 41%, to 67,918 total leukocytes
(Figure 3A). Populations of CD4+ Tcells (P < 0.01; Figure 3B),
monocytes (P < 0.0.05; Figure 3C), and activated macro-
phages (P < 0.05; Figure 3D) were lowered by prior RHP
to levels indistinguishable from the uninjured hemisphere
(Additional file 2: Figure S2B,E,F). However, RHP minim-
ally diminished B cell diapedesis (21,730 cells; Figure 3G),
that, in conjunction with the decreased diapedesis of other
subsets, increased the percent representation of B cells
from 31 % in untreated post-stroke cortex to ~47% of all
identified leukocytes in the protected CNS (Figure 3I).
This shift toward increased B cell representation reflected
the contralateral hemispheres, with only a modest
RHP-induced increase from ~47% B cell representation
in untreated, uninjured cortex to ~50% in RHP-treated,
uninjured cortex (Figure 3K). RHP treatment therefore
restored the ratio of B cells:monocytes (1.3 B cells:
monocytes) [26,27] in the ischemic hemisphere compared
to the untreated cohort (0.63 B cells:monocytes; Figure 3L),
which was identical to the ratio in contralateral hemi-
spheres. Minimal changes in peripheral immunophenotype
were noted (Figure 3M,N; Additional file 3: Figure S3).
Taken together, the analysis of percentage and counts
revealed a reversal of cellularity in the ischemic cortex of
RHP-treated mice similar to the pre-clinical conditions
found in the uninjured cortex.
Repetitive hypoxic preconditioning induces an
immunosuppressed phenotype in resident B cells prior to
stroke onset
To assess if RHP could alter B cell immunophenotype
prior to stroke onset, resident splenic B cells were isolated
for microarray analysis 2 weeks following the completion
of RHP (Additional file 4: Figure S4). We discovered that
the CD19+ B cells exhibited gene expression profiles witha distinct clustering (Figure 4A) from four out of five
RHP-treated mice (excluding RHP #5). B cells from RHP-
treated mice had altered expression of over 1,900 genes
compared to 18,099 genes identified in untreated control
B cells, with the top 10 up- and downregulated genes
listed in Figure 4B (top 50 up- and downregulated genes
listed in Tables 1 and 2). Figure 4C shows the canonical
pathways activated in RHP-treated B cells, which include
a predominant downregulation of genes expressed by B
cells that are important for T cell differentiation and sig-
naling. Interestingly, seven of the top canonical pathways
include key components in B-T cell interactions that
would significantly alter inflammatory responses. Reana-
lyzing the data set to focus on B-T cell interactions
highlighted significant downregulation (all z scores > −2)
of the quantity of T cells (P = 7.4E-05), differentiation of
CD4 T cells (P = 2.6E-04), and the immune response of
cytotoxic CD8 T cells (P = 2.1E-03). Both CD4 and CD8 T
cell subtypes have been previously implicated in the pro-
gression of neurovascular injury following stroke [4,10,14]
and remain downregulated in ischemic hemisphere of
RHP-treated mice after stroke (Figure 3). In addition,
upstream analysis showed a predicted activation of
interleukin-4 (P = 1.5E-02; Figure 5A) and subsequent
inhibition of the downstream transcriptional regulators
interferon regulatory factor (IRF)-1, IRF4, IRF8, and the
cytokine TNF-α.
The RHP-induced regulation of CD4 T cell differentiation
(21/68 genes differentially affected; 52% of altered genes
downregulated; P = 3.0E-06) included a staggering 6,800-
fold downregulation of histocompatibility 2, O region
beta locus (H2-Ob), the homolog to human HLA-DOB
(Figure 5B). HLA-DOB is selectively expressed in B cells
and required for B cell antigen presentation under the
transcriptional regulation of the major histocompatibility
complex (MHC) class II transactivator CIITA [28], with the
mouse homolog Ciita also downregulated in RHP-treated B
cells (−1.68-fold; P = 4.6E-06). The canonical pathway
with the greatest downregulation and second-highest
significance was the antigen presentation pathway (13/29
genes differentially affected; 85% of altered genes down-
regulated; P = 3.5E-06). Other B cell-specific biological
functions significantly downregulated (all z-scores > −2)
include hematopoiesis, development and differentiation
of lymphocytes, and the production of antibody (Figure 5C).
These microarray data suggest that RHP suppresses the
proliferation, development, and differentiation of B cells,
in addition to inhibiting B-T cell adaptive immune interac-
tions, weeks after completion of RHP and prior to stroke
onset.
To gain a deeper understanding of our microarray
results, we characterized splenic B cell populations from
RHP-treated mice and performed an ex vivo phenotype
analysis using flow cytometry. As B cells mature, they
Figure 3 (See legend on next page.)
Monson et al. Journal of Neuroinflammation 2014, 11:22 Page 7 of 18
http://www.jneuroinflammation.com/content/11/1/22
(See figure on previous page.)
Figure 3 Repetitive hypoxic preconditioning recruits B cells into the ischemic cortex following stroke. (A-G) Overall leukocyte diapedesis
was diminished in the ischemic cortex of repetitive hypoxic preconditioning (RHP)-treated mice (blue circles; n = 15) compared to control mice
exposed to room air (21 % oxygen) without preconditioning (black circles; n = 12). Specifically, RHP reduced the mean populations (blue bars) of
CD4+ T cells, monocytes, and macrophages in the ischemic hemispheres to levels indistinguishable from the contralateral hemispheres (shown in
Additional file 2: Figure S2). Mean shown below each graph in thousands. (H-N) The distribution of identified leukocyte subsets from the (H,I)
ischemic cortex and (J,K) contralateral (that is, uninjured) cortex (Additional file 2: Figure S2), with (L) ratios identified. (M,N) Peripheral blood of
the same animals (Additional file 3: Figure S3) is shown, with total number of immune cells shown below. RHP-treated mice clearly have an
increased recruitment of B cells in the ischemic cortex. Mean ± SD. Data represent four independent experiments.
Figure 4 Repetitive hypoxic preconditioning induces an immunosuppressive phenotype prior to stroke. B cells isolated from spleen were
analyzed with microarray, showing (A) distinct clustering of repetitive hypoxic preconditioning (RHP)-treated mice compared to controls (21 %;
n = 5/group). (B) Top 10 up- and downregulated genes, and (C) top activated canonical pathways are shown. Gene products are shown in bar
graph form as percentages of all genes associated with a listed pathway (upper axis). Gene numbers up/downregulated are located in the bars, with
the total number of genes within the pathway shown to the right. Expression changes are shown as either upregulated (red bars) or downregulated
(green bars), and pathways with B-T cell interactions are marked by a cross. Respective P values are indicated by orange squares (lower axis). Replicate
samples on the microarray chip are indicted with (R) in panel A.
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Table 1 Top 50 upregulated genes isolated from repetitive hypoxic preconditioning-treated splenic B cells compared
to untreated splenic B cells
Accession Symbol Fold change P value Abbreviated definition
NM_010474.1 Hs3st1 14.00 1.38E-09 Heparan sulfate (glucosamine) 3-O-sulfotransferase 1 (Hs3st1)
NM_013498 Crem 7.90 4.02E-02 cAMP responsive element modulator (Crem), transcript variant 3
NM_013498 Crem 7.74 1.93E-02 cAMP responsive element modulator (Crem), transcript variant 3
NM_145552 Gnl2 4.70 2.78E-02 Guanine nucleotide binding protein-like 2 (nucleolar) (Gnl2)
NM_026301.1 Rnf125 4.61 4.29E-02 Ring finger protein 125 (Rnf125)
NM_027950.1 1700012B18Rik 4.35 1.76E-08 Oxidative stress induced growth inhibitor 1 (Osgin1), nuclear gene
encoding mitochondrial protein
NM_013498.1 Crem 4.21 1.57E-02 cAMP responsive element modulator (Crem), transcript variant 3
AK053379 E130012P04Rik 4.13 1.34E-02 CDNA FLJ20330 FIS, CLONE HEP10296 homolog [Homo sapiens],
full insert sequence
NM_009368.1 Tgfb3 4.07 2.58E-02 Transforming growth factor, beta 3 (Tgfb3)
XM_144142.3 1810045K06Rik 3.72 5.20E-04 Kelch-like 21 (Klhl21)
NM_019980 Litaf 3.58 1.05E-02 LPS-induced TN factor (Litaf)
NM_010831.1 Snf1lk 3.57 2.21E-04 Salt inducible kinase 1 (Sik1)
XM_138460.2 LOC218060 3.23 4.61E-02 -This record was discontinued.
NM_177091.2 Fndc7 3.16 3.81E-04 Fibronectin type III domain containing 7 (Fndc7), transcript variant 1
NM_177876.2 BC026744 3.16 2.07E-07 Vacuolar protein sorting 37B (yeast) (Vps37b)
NM_145222.1 B3gnt7 3.12 8.64E-11 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase
7 (B3gnt7)
NM_178149.2 1500004A08Rik 3.04 1.76E-06 Phosphoinositide-3-kinase interacting protein 1 (Pik3ip1)
NM_053272 Dhcr24 2.92 4.08E-03 24-dehydrocholesterol reductase (Dhcr24)
XM_354933.1 2410015A16Rik 2.87 2.41E-02 Lymphocyte antigen 6 complex, locus K (Ly6k)
NM_145559.1 Slc2a9 2.87 1.70E-02 Solute carrier family 2 (facilitated glucose transporter), member 9
(Slc2a9), transcript variant 4
AK037598 Stat4 2.82 4.05E-02 Signal transducer and activator of transcription 4, full insert sequence
NM_007393.1 Actb 2.77 1.08E-10 Actin, beta (Actb)
NM_134109.1 Ildr1 2.76 6.72E-03 Immunoglobulin-like domain containing receptor 1 (Ildr1)
NM_011742.1 Zfp1 2.75 5.42E-03 Zinc finger protein 1 (Zfp1), transcript variant 2
AK047415 B930059G07Rik 2.75 7.90E-03 HEMATOPOIETIC CELL PROTEIN-TYROSINE PHOSPHATASE
70Z-PEP (EC 3.1.3.48)
NM_009883.1 Cebpb 2.73 3.37E-05 CCAAT/enhancer binding protein (C/EBP), beta (Cebpb)
NM_007393.1 Actb 2.65 4.10E-10 Actin, beta (Actb)
AK038223 A130087I02Rik 2.65 1.16E-02 RIKEN full-length enriched library, clone:A130087I02 product:
unclassifiable, full insert sequence
XM_148086.4 LOC224137 2.64 8.14E-03 -This record was discontinued.
AK053596 E130112N23Rik 2.63 4.30E-05 RIKEN full-length enriched library, clone:E130112N23 product:
hypothetical protein, full insert sequence
NM_026301.1 Rnf125 2.63 4.68E-02 Ring finger protein 125 (Rnf125)
NM_027013.1 Scnm1 2.61 1.07E-02 Sodium channel modifier 1 (Scnm1), transcript variant 1
NM_144554.1 Trib3 2.55 7.58E-03 - tribbles homolog 3 (Drosophila), validated
AK039925 A430031F07Rik 2.54 3.29E-03 RIKEN full-length enriched library, clone:A430031F07 product:
hypothetical protein, full insert sequence
XM_358387.1 Crsp2 2.53 2.36E-02 Mediator complex subunit 14 (Med14), transcript variant 2
NM_172934.1 4632417D23 2.47 4.75E-04 -"This RefSeq was permanently suppressed because currently
there is insufficient support for the protein."-
AK041320 Icosl 2.47 4.97E-05 Icos ligand, full insert sequence
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Table 1 Top 50 upregulated genes isolated from repetitive hypoxic preconditioning-treated splenic B cells compared
to untreated splenic B cells (Continued)
NM_009546.1 Trim25 2.47 2.45E-03 Tripartite motif-containing 25 (Trim25)
NM_180974.1 Foxn2 2.46 1.09E-03 Forkhead box N2 (Foxn2)
NM_172442.2 Dtx4 2.42 2.23E-02 Deltex 4 homolog (Drosophila) (Dtx4)
NM_019518.2 Grasp 2.41 1.48E-04 GRP1 (general receptor for phosphoinositides 1)-associated
scaffold protein (Grasp)
AK052205 D330008I21Rik 2.39 3.03E-08 RIKEN full-length enriched library, clone:D330008I21 product:
hypothetical protein, full insert sequence
NM_134109.1 Ildr1 2.38 1.33E-05 Immunoglobulin-like domain containing receptor 1 (Ildr1)
NR_027901.1 2900060B14Rik 2.37 3.51E-17 RIKEN cDNA 2900060B14 gene (2900060B14Rik), non-coding RNA
2010204O13Rik 2.36 4.00E-02 Replaced with tetratricopeptide repeat domain 19 and validated
NM_025549.1 Arrdc4 2.35 4.64E-02 Arrestin domain containing 4 (Arrdc4), transcript variant 2
AK041549 A630020I15Rik 2.32 6.38E-04 Similar to TYROSINE-PROTEIN KINASE JAK3 (EC 2.7.1.112) (JANUS
KINASE 3) (JAK-3) [Mus musculus]
NM_029083.1 Ddit4 2.32 3.87E-03 DNA-damage-inducible transcript 4 (Ddit4)
AK020047 6030405P19Rik 2.29 2.67E-11 TRUNCATED BRE ALPHA A3+ ISOFORM homolog [Homo sapiens],
full insert sequence
NM_009843.2 Ctla4 2.27 4.44E-03 Cytotoxic T-lymphocyte-associated protein 4 (Ctla4)
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and thus increase their ability to interact with T cells
[22]. We therefore evaluated the ex vivo maturation
status of splenic B cells by first evaluating the frequency of
transitional (T1, T2 and T3) B cells. T1 B cells do not mi-
grate to lymph nodes and, while T3 B cells express higher
levels of B220, they are distinct from mature B cells [22].
Gating on CD19+CD93+ B cells and using IgM versus
CD23 in order to discriminate between the transitional
populations (Additional file 5: Figure S5), we observed a
significant increase in T1 cells isolated from RHP-treated
mice compared to untreated mice (14.32% vs 11.70%,
respectively; P < 0.01; Figure 6A). RHP therefore reduced
the resident pool of B cells capable of antigen presenta-
tion, as MHC class II and CD21/CD35 expression is
lowest in the T1 stage [22]. RHP also inhibits fully acti-
vated B cell status by inducing a concomitant increase in
early (IgM+IgD-CD19+) and mid-phase (IgM+IgD+CD19+)
B cells (3.24% vs 5.3%; P < 0.01, 14.52% vs 22.07%; P <
0.01, respectively) and decrease in late activation-phase
(IgMlowIgD+CD19+) B cells (72.88 % vs 59.17 %; P < 0.0001)
compared to untreated mice (Figure 6B). Our microarray
data also indicated a downregulation of B-T cell interac-
tions. Evaluation of follicular B cells, which are known
to require T cell help [29], showed no effect of RHP on
B cell representations in the marginal or follicular zones
(Figure 6C). Finally, we confirmed an RHP-induced im-
munosuppression of the proliferative capacity of B cells
by performing an in vitro CFSE dilution assay. RHP-
modulated B cells were incapable of responding to
polyclonal stimuli such as LPS (delta proliferation fraction(dPF) = 14.48% vs 4.15%; P < 0.05) or phorbol myristate
acetate (dPF = 65.55% vs 27.80%; P < 0.05; Figure 6D).
Taken together, these data suggest a preferential action
of RHP on B cell-mediated adaptive immune mechanisms
[30] by significantly reducing mature and activated B cells in
the peripheral immune compartment prior to stroke onset.
Repetitive hypoxic preconditioning induces a regulatory
B-cell population
B10 cells (that is, regulatory B cells), with enhanced IL-10
expression, can suppress CNS disease progression for
several inflammatory autoimmune diseases in both mice
[6,31-33] and humans [34]. A newly emerging hypothesis
[9] is that B10 cells can enhance protection from stroke-
induced injury by limiting the diapedesis of other leukocyte
subsets when delivered 24 hours prior to stroke onset in B
cell-deficient mice [6,7]. Since this observation reflected the
impact of RHP on post-stroke cortical leukocyte dynamics,
we investigated whether RHP treatment induced or
augmented the regulatory B cell repertoire through en-
dogenous mechanisms prior to any CNS injury. Using
the regulatory B cell gating strategy (Additional file 5:
Figure S5), we observed an increase in CD1dhiCD5+
regulatory B cells in RHP-treated mice compared to
untreated mice (11 % vs 7 %; P < 0.05; Figure 7). Conven-
tional B1a and B2 B cell populations were unchanged. Pre-
conditioning by repeated exposures to systemic hypoxia
results in a lower disease severity [1], which correlates
with a modulation of the B cell immune compartment,
and suggests a novel induction of a regulatory circuitry
resulting in a lower disease incidence.
Table 2 Top 50 downregulated genes isolated from repetitive hypoxic preconditioning-treated splenic B cells compared
to untreated splenic B cells
Accession Symbol Fold change P value Abbreviated definition
NM_010389 H2-Ob −6801.35 1.57E-03 Histocompatibility 2, O region beta locus (H2-Ob)
NM_010238.1 Brd2 −65.77 1.66E-03 Bromodomain containing 2 (Brd2), transcript variant 1
XM_132218.3 2310002F18Rik −43.53 3.68E-38 Coenzyme Q2 homolog, prenyltransferase (yeast) (Coq2),
nuclear gene encoding mitochondrial protein
NM_053214.1 Myo1f −15.52 2.26E-03 Myosin IF (Myo1f)
AK037780 Slam −8.51 2.00E-03 Signaling lymphocyte activation molecule, full insert
sequence
NM_008533 Ly78 −7.47 1.60E-03 CD180 antigen (Cd180)
XM_284165.2 A730013O20Rik −6.59 1.23E-02 Microtubule associated tumor suppressor candidate
2 (Mtus2)
XM_194143.2 LOC269542 −5.95 7.67E-06 -This record was discontinued.
NM_026216.1 1700096C12Rik −5.71 1.07E-03 Replaced with F-box protein 4 and validated
AK043442 Cd38 −5.50 7.29E-08 CD38 antigen, full insert sequence
AK051496 D130052N13Rik −5.37 1.86E-02 RIKEN full-length enriched library, clone:D130052N13
product:hypothetical protein, full insert sequence
AK029383 4833419P04Rik −5.24 4.42E-07 RIKEN full-length enriched library, clone:4833419P04
product:hypothetical protein, full insert sequence
NM_011579.2 Tgtp −5.15 2.09E-03 T cell specific GTPase 1 (Tgtp1)
NM_011926.1 Ceacam1 −5.09 4.97E-02 Carcinoembryonic antigen-related cell adhesion
molecule 1 (Ceacam1), transcript variant 3
AK045295 Swap70 −5.06 1.36E-12 SWAP complex protein, 70 kDa, full insert sequence
XM_359052.1 LOC386068 −4.88 2.49E-05 -This record was discontinued.
XM_357708.1 LOC384553 −4.81 8.72E-06 -This record was discontinued.
AK085749 Ceacam1 −4.59 3.50E-02 CEA-related cell adhesion molecule 1, full insert sequence
AK080623 A830029A02Rik −4.27 6.89E-04 RIKEN full-length enriched library, clone:A830029A02
product:hypothetical protein, full insert sequence
XM_205896.3 LOC277506 −4.23 2.27E-03 -This record was discontinued.
AK038943 A230077I10Rik −4.18 3.45E-02 Similar to ENDOGLYCAN, full insert sequence
NM_175128 4930430F08Rik −4.03 1.02E-02 RIKEN cDNA 4930430 F08 gene (4930430F08Rik),
protein coding
XM_150371.1 1700016D02Rik −4.01 1.45E-02 RIKEN cDNA 1700016D02 gene , protein coding
AK040329 Tactile-pending −3.84 3.10E-04 T cell activation, increased late expression, full insert
sequence
NM_177588.1 AW413632 −3.82 1.26E-02 threonine synthase-like 1 (bacterial) (Thnsl1), transcript
variant 1
NM_008493.3 Lep −3.63 6.19E-03 Leptin (Lep)
NM_145145.1 Pomt1 −3.62 8.42E-03 protein-O-mannosyltransferase 1 (Pomt1)
AK041764 Rasgrf2 −3.56 6.48E-03 RAS protein-specific guanine nucleotide-releasing
factor 2, full insert sequence
AK011989 2610305J24Rik −3.49 1.38E-03 RIKEN full-length enriched library, clone:2610305 J24
product:unclassifiable, full insert sequence
XM_359103.1 LOC386168 −3.42 1.54E-02 -This record was discontinued
AK035999 9630025O15Rik −3.34 2.11E-02 RIKEN full-length enriched library, clone:9630025O15
product:hypothetical protein, full insert sequence
NM_028595 Ms4a6c −3.32 1.46E-03 Membrane-spanning 4-domains, subfamily A, member
6C (Ms4a6c), transcript variant 1
NM_010797.1 Mid1 −3.31 1.55E-05 Midline 1 (Mid1), transcript variant 1
NM_024291.3 Ky −3.22 9.05E-03 Kyphoscoliosis peptidase (Ky)
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Table 2 Top 50 downregulated genes isolated from repetitive hypoxic preconditioning-treated splenic B cells compared
to untreated splenic B cells (Continued)
AK080934 Ly116 −3.21 9.86E-03 Membrane-spanning 4-domains, subfamily A, member
4B, full insert sequence
XM_140160.2 LOC240168 −3.20 6.52E-03 RAS, guanyl releasing protein 3 (Rasgrp3), transcript
variant 2
AK034620 9430015G10Rik −3.17 1.64E-02 RIKEN full-length enriched library, clone:9430015G10,
protein coding, validated
AK089281 Traf1 −3.13 4.00E-02 Tnf receptor-associated factor 1, full insert sequence
XM_148699.3 Crebbp −3.08 1.25E-12 CREB binding protein (Crebbp)
BC016202 Dhx30 −3.03 2.02E-02 DEAH (Asp-Glu-Ala-His) box polypeptide 30, mRNA
(cDNA clone MGC:27662 IMAGE:4527765), complete cds
AK044748 A930039F13Rik −2.98 2.72E-04 Hypothetical RNA-binding region RNP-1
(RNA recognition motif) containing protein, full insert
sequence
NM_013730.2 Slamf1 −2.96 4.44E-16 Signaling lymphocytic activation molecule family
member 1 (Slamf1)
NM_009744.2 Bcl6 −2.93 8.88E-16 B cell leukemia/lymphoma 6 (Bcl6)
XM_285750.2 LOC332788 −2.91 3.46E-02 -This record was discontinued
NM_177197.2 4833405L16Rik −2.83 3.82E-03 Isopentenyl-diphosphate delta isomerase 2 (Idi2)
NM_008739 Nsd1 −2.80 1.67E-13 Nuclear receptor-binding SET-domain protein 1 (Nsd1)
NM_001039250.1 EG638695 −2.79 2.82E-02 Predicted gene 7247
NM_011538.1 Tbx6 −2.76 3.57E-03 T-box 6 (Tbx6)
XM_358291.1 LOC385575 −2.76 3.08E-08 -This record was discontinued
XM_132034.1 Pcdh7 −2.76 3.92E-02 Protocadherin 7, protein coding, validated
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We previously showed that RHP induced a protective
phenotype from stroke-induced neurovascular injury by
downregulating neuroinflammatory mechanisms within
the ischemic brain [1]. In this study, we confirmed that
RHP continues to attenuate neutrophil diapedesis at 2
days post-stroke and showed that the leukocyte subtypes
blocked by RHP also include T cells, monocytes, and acti-
vated macrophages. In contrast, B cells are actively main-
tained in the ischemic hemisphere of RHP-treated mice,
which correlated with an earlier upregulation of CXCL13
that, taken together with the attenuation of diapedesis,
created a distribution of leukocyte subsets indistinguish-
able from the uninjured, contralateral hemisphere. Ratios
of immune cells, and particularly B cells:monocytes, have
been used to define a pathological immune microenviron-
ment in patients with autoimmune disease [27], and more
recently B cell lymphoma [26,35], though the profile for
patients with stroke is currently uninvestigated. For patients
with multiple sclerosis, higher disease progression was as-
sociated with higher B cell and lower monocyte numbers
[27]. In contrast, our B cell:monocyte ratios within the
CNS suggest that higher B cell numbers, when compared
to monocyte representations, are the steady-state distribu-
tion profile within the uninjured CNS of the contralateral
hemisphere that is maintained in the ischemic hemisphere
of RHP-treated mice.These findings are consistent with the emerging concept
of a potential for B cell-mediated protection from stroke-
induced neurovascular injury [9]. Work from Offner and
colleagues show that B cell deficiency in transgenic mice
increases ipsilesional leukocyte diapedesis post-stroke, while
adoptive transfer [6,7] and intrastriatal injection [8] to
restore B cells reduce infarct volumes and neurological
deficits. These authors suggest that B cells secreting IL-10,
a known post-stroke neuroprotectant [36], reduce ischemic
injury by modulating subsequent neutrophil diapedesis
and pro-inflammatory chemokine production [37-39].
While RHP could enhance sequestering of pro-inflam-
matory leukocyte subsets in other peripheral organs,
including the liver [40], after stroke, we found no effect
on peripheral leukocyte counts in animals with attenuated
diapedesis in the ischemic hemisphere. In fact, elevated
peripheral neutrophils in RHP-treated mice were actively
blocked from entry into the protected CNS. Therefore,
our mouse model of RHP suggests a novel intervention
that creates a naturally protective phenotype that augments
the potential for B cell-mediated neuroprotection [1], but
without genetic or pharmacologic perturbation of the
immune system.
The immunosuppressive B cell phenotype induced in
RHP-treated mice (prior to stroke) suggests novel adaptive
mechanisms for B cell-mediated protection from stroke.
Lymphocytes encounter CNS-derived antigens upon BBB
Figure 5 (See legend on next page.)
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Figure 5 Repetitive hypoxic preconditioning suppresses adaptive immune responses in resident B cells prior to stroke. (A) Microarray
analysis predicted a repetitive hypoxic preconditioning (RHP)-induced activation of IL-4 in B-T cell interactions to suppress downstream transcriptional
regulators interferon regulatory factor (IRF)1, IRF4, and IRF8 and the cytokine TNF. Downstream molecules are coded for upregulation (red) and
downregulation (green) according to expression in the data set. Blue lines lead to inhibition, whereas yellow lines indicate interactions inconsistent
with the state of the downstream molecule. (B) Major histocompatibility complex (MHC)-related transcription and receptor responses in RHP-treated B
cells. All molecules shown are significantly downregulated (green) or upregulated (red) by RHP and are identified by gene name with the human
homolog in parentheses below. (C) Heat map showing downregulated (blue) and upregulated (orange) biological function pathways related to
protein synthesis, including antibody production, in RHP-treated B cells compared to untreated control mice. Significance is only shown for pathways
with z-score > −2. All significance and graphs generated by Ingenuity Pathway Analysis software.
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initiate potentially harmful, acute autoimmune responses
(see reviews [18,41]). Additionally, peripheral and resident
dendritic cells upregulate MHC II receptors following
transient focal stroke, with peak expression occurring
3 days after stroke onset [42]. MHC II receptors coloca-
lized with brain-derived antigen in the cervical lymph
nodes and palatine tonsils of stroke patients [43], with
neuronally-derived epitopes correlating with smaller
infarct volumes and better functional recovery, and
myelin-derived epitopes correlating with larger infarct
volumes. However, immune tolerance to myelin basicFigure 6 Repetitive hypoxic preconditioning treatment modulates the
system injury. (A) Transitional state of CD19+CD93+ B-cells were quantifie
cells. Repetitive hypoxic preconditioning (RHP) suppresses the maturation o
was analyzed by quantifying the level of early (IgM+IgD-), mid (IgM+IgD+) o
in the resident B-cells. (C) Conventional B-cell subtypes such as marginal zo
CD93- populations and not affected by RHP. (A-C) n = 6/group; two indepe
assessed using carboxyfluorescein succinimidyl ester (CFSE) dilution assay w
(dPF) is the percentage of CFSE low cells in the test condition (stimulated) mi
two independent experiments with n = 4 per condition. Mean percentages ±protein prior to stroke improved functional recovery in
mice [44]. These data highlight the complex interplay
between antigen presentation and injury in the ischemic
brain. Unfortunately, studies of the role of B cell antigen
presentation following stroke are limited. Our microarray
analysis revealed that RHP suppresses B cell antigen pres-
entation prior to stroke in protected mice via downregula-
tion of the master transcriptional regulator CIITA [28]
and several downstream MHC I and MHC II receptors.
Of note, RHP simultaneously and selectively upregu-
lated the expression of H2-Ea-ps, a homolog for human
HLA-DR (Figure 5B). Loss of HLA-DR, an MHC IIperipheral B-cell immune compartment prior to central nervous
d and measured as T1 (IgM+CD23-), T2 (IgM+CD23+) or T3 (IgM-CD23+)
f B-cells from T2 to T3 stage. (B) Ex vivo splenic B-cell activation status
r late (IgM-IgD+) CD19+ B-cells. RHP inhibits fully activated B-cell status
ne (MZ) and follicular B-cells (FOB) were quantified within the CD19+
ndent experiments. (D) In vitro polyclonal B cell responses were
ith lipopolysaccharide (LPS) stimulation. Delta proliferation fraction
nus the background (non-stimulated condition). Data is representative of
SD are shown. 21 %, Untreated cohorts; PMA, phorbol myristate acetate.
Figure 7 Repetitive hypoxic preconditioning treatment specifically induces an immunosuppressive regulatory B-cell population prior
to central nervous system injury. Ex vivo regulatory B-cell levels from repetitive hypoxic preconditioning (RHP)-treated mice relative to untreated
(21 %) cohorts. B10 (CD1dhiCD5+), B1a (CD1d+CD5+) and conventional B2 (CD1dlowCD5-) subpopulations were quantified within splenic CD19+
B-cells populations. Mean percentages ± SD are shown; n = 6/group; two independent experiments.
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ive of post-stroke infection, which impeded long-term re-
covery of these patients [45] and emphasizes the
complexity of endogenous adaptive immunity following
RHP.
Upon exiting the bone marrow, B cells are specifically
recruited to the spleen where they mature to proliferate,
produce antibodies and secrete cytokines when activated
by antigen. When antigen is removed, a selected few
remain in a sustained memory state until a rapid response
is needed upon subsequent presentation of the antigen
during adaptive immunity [46]. Antibody production is
typically studied under states of infection or auto-immune
disorders, but little is known about antibody-producing
plasma cell immune responses during cerebral ischemia
or endogenous neurovascular protection. In our model,
the immune function with the greatest RHP-induced
modulation prior to stroke was the downregulation of
the antibody response. In addition, the transcriptional
repressor B cell lymphoma (Bcl)-6 and Bcl-6 interact-
ing co-repressor are both significantly downregulated
(Table 2), possibly to minimize germinal center develop-
ment and thus antibody-mediated immune responses [46]
should injury occur. RHP decreased the repertoire of
mature B cells, while increasing regulatory B cells, by
increasing T1 and IgM+IgD- B cells, with concomitant
reduction of IgM-IgD+ B cells, an effect which may be
occurring through either inhibition of B cell maturation
and/or selective depletion of mature cells. Reduction in
peripheral mature B cells (that is, IgD-expressing cells)
induces tolerance in murine autoimmune studies and
pan-mature B-cell depletion in human CNS diseases
[47-49]. Although transitional B cells are capable of anti-
gen presentation, they were found to be poor activators of
naïve CD4 T-cells [50].
We hypothesize that RHP inhibits B cell-mediated
immune mechanisms, which potentially promote acuteinjury, while simultaneously augmenting disease-inhibiting
regulatory B cells, a complex interplay of adaptive immune
mechanisms also identified in autoimmune disease [51]
that will be addressed in future studies. It remains un-
clear whether antibodies are produced during the initial
exposures to hypoxia at the start of RHP to mediate
adaptive immunity resulting in subsequent post-stroke
immunosuppression [18]. Furthermore, RHP is systemic
stimuli that may influence B cell development in the
bone marrow compartment, which serves as a contem-
poraneous B cell maturation and activation site to the
spleen [52]. The egress of mature B cells from the bone
marrow typically occurs within 5 days, a more rapid rate
than during splenic maturation [52]. Therefore, our ana-
lysis of stable, immature B cell phenotypes at 14 days after
RHP in the spleen most likely reflects a similar profile
within the bone marrow, though this observation needs
to be experimentally confirmed. Future studies will also
elucidate the role of antigen presentation and antibody
production in the establishment of endogenous neuro-
vascular protection, in addition to the progression of
post-stroke injury and repair.
Our findings identified the upregulation of CXCL13
within the BBB in response to stroke (Figures 1 and 2).
Stroke induced a predominantly vascular expression of
CXCL13 protein throughout the ischemic hemisphere,
though others show both astrocytes [53] and stimulated
neurons [54] can upregulate this chemokine during in-
flammation. While early upregulation of CXCL13 mRNA
in RHP-treated mice could potentially allow for the
selective recruitment of post-stroke B cells into the pro-
tected brain in the absence of other leukocyte populations,
CXCL13 mRNA is equally upregulated in the untreated
ischemic BBB by 2 days following stroke onset. This
may prove beneficial in future studies investigating the
potential for the transfer of B cell-mediated neurovascu-
lar protection to naïve mice after stroke, as selective
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sole by-product of the RHP treatment. It will also improve
the translation of pro-recovery B cells as a potential
neurotherapeutic if we can determine if the presence of
reprogrammed B cells in the ischemic cortex promotes
long-term recovery mechanisms, such as neuronal plasticity
and angiogenesis. Activated, but not resting, B cells are
the major producers of lymphocyte-derived brain-derived
neurotrophic factor in mouse and humans [54,55] and, as
brain-derived neurotrophic factor secretion by B cells
supports neuronal survival both in vitro [54] and in vivo
[56,57], it is imperative to discover in future studies if
RHP alters post-stroke B cells to enhance the upregulation
of this, and other growth factors, in the post-stroke brain.
Conclusions
With this data, we describe for the first time the expression
pattern of the chemokine CXCL13 following stroke, and
the novel maintenance of B cells in the protected ischemic
cortex. We also identified an adaptive B cell immuno-
phenotype following brief systemic hypoxia that includes
downregulation of antigen presentation and antibody pro-
duction within the quiescent immune system. In humans,
living at high altitudes [58], pre-stroke exercise [59], and
prior limb ischemia [60-62] all mitigate the severity of
ischemic injury. It is unknown how these systemic precon-
ditioning interventions reduce injury, though a recent clin-
ical study shows that remote ischemia confers myocardial
protection in infants through the upregulation of IL-10
[62]. Our observation of RHP-induced B cell recruitment
may be the first step to understanding the role of adaptive
immunity in mitigating the severity of ischemia – or other
injuries – within the CNS and other organs. Ultimately,
understanding the mechanisms by which the CNS chooses
to protect itself is foundational to developing effective
therapies, not only for the treatment of stroke-related
injury, but potentially for other diseases that involve either
a loss of BBB integrity or the recruitment of leukocytes
into the parenchyma.
Additional files
Additional file 1: Figure S1. Gating strategies for the ischemic cortex
and peripheral blood samples following stroke. Gating strategies from (A)
perfused ischemic and contralateral hemispheres and (B) peripheral
blood. Specific leukocyte populations are identified in the gating.
Additional file 2: Figure S2. Repetitive hypoxic preconditioning (RHP)
continues to block leukocyte diapedesis into the ischemic cortex at 2
days following stroke. (A-G) Percent representation (top panel) and total
count (bottom panel) shown for each gated leukocyte subset for the
ischemic (filled circles) and contralateral (open circles) cortex. RHP decreased
leukocyte diapedesis into the ischemic cortex of RHP-treated mice (blue
symbols) at 2 days after transient middle cerebral artery occlusion (tMCAo)
compared to control mice without preconditioning (21%; black symbols;
n = 3 animals/point; n = 12–21 animals/group; hemocytometer counts were
not collected for one experiment). RHP reduced CD4+ T-cells, monocytes,and macrophages in the ischemic hemispheres to levels indistinguishable
from the contralateral hemispheres. Mean (bars) ± standard deviation (SD;
whiskers); *P < 0.05; **P < 0.01; *vs contralateral cortex unless otherwise
designated by a horizontal bar.
Additional file 3: Figure S3. Repetitive hypoxic preconditioning (RHP)
recruits B-cells from the periphery while actively blocking neutrophil
diapedesis. (A-G) Percent representation (top panel) and total count (bot-
tom panel) shown for each gated leukocyte subset quantified in
peripheral blood. Only (F) neutrophil and (G) B-cell representations were
affected by prior RHP (n = 12) compared to control (n = 24). Distribution
of leukocyte subsets for cellular leukocyte counts are shown in Figure 3.
Mean (bars) ± standard deviation (SD; whiskers); *P < 0.05 vs untreated
mice.
Additional file 4: Figure S4. Repetitive hypoxic preconditioning (RHP)
minimally alters peripheral lymphocyte representation prior to stroke.
Two weeks following RHP (blue symbols; n = 5), (A,B) leukocyte
representation in peripheral blood and spleen was quantified and
compared to 21% O2 controls (black symbols; n = 5). RHP diminished
percent representation of B cells in blood, and CD8 T cells in spleen. A
trend for an increase in neutrophil representation in the spleen was
significant in (C) splenic leukocyte counts. While RHP-treated mice had
more splenic leukocytes, (D) overall distributions of subsets were similar.
B cells isolated for microarray analysis are designated by the red outline.
*P < 0.05 vs 21% O2 controls. Data were collected on the same day for
microarray analysis.
Additional file 5: Figure S5. Flow cytometric analysis of B-cell
immunophenotype after repetitive hypoxic preconditioning (RHP) modulation.
(A) Gating strategies for assessment of B-cell maturation and activation in
RHP-treated resident B-cells (n = 6) relative to untreated control (21%)
cohorts (n = 6). (B) Gating strategy to quantify regulatory (B10 and B1a)
and conventional (B2) B-cells in RHP treated mice. Data represent two
independent experiments.Abbreviations
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